Also trades as: DRUG (NASDAQ) · $vol 12M
DRUG.CN CNQ
Bright Minds Biosciences Inc.
1W: -12.3%
1M: -17.0%
3M: -10.6%
YTD: -0.7%
1Y: +123.6%
3Y: +1667.9%
C$111.57 ($81.03)
+7.84 (+7.56%)
Weekly Expected Move ±8.1%
C$89
C$98
C$107
C$115
C$124
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market CapC$805.1M ($584.7M)
52W Range33.01-170
Volume1,102
Avg Volume826
Beta-0.19
Dividend—
Analyst Ratings
Company Info
CEOIan McDonald
Employees26
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-09
Websitebrightmindsbio.com
1500 â 1055 West Georgia Street
New York City, BC V6E 4N7
CA
New York City, BC V6E 4N7
CA
647 407 2515
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Latest News
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages
HC Wainwright Brokers Raise Earnings Estimates for DRUG
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of “Moderate Buy” by Brokerages
Recent Insider Trades
No insider trades found